What is the recommended management for an enteroenteric fistula in Crohn's disease?

Management of Enteroenteric Fistula in Crohn's Disease

For enteroenteric fistulas in Crohn's disease, asymptomatic fistulas require no treatment, while symptomatic fistulas necessitate surgical resection of the diseased bowel segment with either suture closure or resection of the affected "victim" segment.

Key Clinical Distinction

The critical first step is determining whether the enteroenteric fistula is causing symptoms:

• Asymptomatic enteroenteric fistulas: No treatment required 1, 2
• Symptomatic fistulas: Surgical intervention indicated 1

This differs fundamentally from perianal fistulas, where medical therapy with biologics is the mainstay of treatment.

Why Medical Therapy Is Not the Answer

The 2021 AGA guidelines explicitly state that "data on drug therapy for types of fistula other than perianal fistula are almost totally lacking" 3. The guideline panel deliberately limited their focus to perianal fistulas because there is essentially no evidence base for medical management of enteroenteric fistulas. The strong recommendations for infliximab and other biologics apply only to perianal fistulizing disease, not internal fistulas 3.

Surgical Approach

When surgery is indicated for symptomatic enteroenteric fistulas:

Standard Surgical Technique

• Resect the diseased bowel segment (the "active" disease site that generated the fistula) 4
• Manage the "victim" segment (the uninvolved bowel where the fistula terminates) by:
  • Simple suture closure (most common) 4
  • Stapled fistulectomy 4
  • Resection if significantly diseased 4
  • En bloc resection of both segments if technically feasible 4

Intraoperative Decision-Making

Intraoperative inspection alone is reliable for determining whether the victim segment requires resection versus simple closure 5. You do not need preoperative endoscopic evaluation of every segment if the fistula is discovered intraoperatively—visual inspection of the bowel wall for active inflammation, thickening, or ulceration is sufficient to guide the surgical decision 5.

Common Pitfalls to Avoid

1. Do not treat the fistula itself as the primary problem: The fistula is a consequence of active Crohn's disease. Direct treatment toward the underlying active or stenotic disease, not the fistula tract 2.

2. Do not use the fistula presence alone as an indication for surgery: Operate based on symptoms (obstruction, malabsorption, sepsis) or complications, not merely because a fistula exists radiologically 2.

3. Do not extrapolate perianal fistula data to enteroenteric fistulas: The robust evidence for anti-TNF therapy in perianal disease does not apply to internal fistulas 3, 6.

When Medical Therapy Has a Role

While biologics are not indicated specifically for enteroenteric fistulas, they should be used to:

• Control active luminal Crohn's disease that may be driving fistula formation 7
• Prevent postoperative recurrence after surgical resection 8

The 2021 AGA guidelines recommend against 5-ASA/sulfasalazine for moderate-to-severe Crohn's disease 3, so these agents have no role in fistulizing disease management.

Surgical Outcomes

The surgical approach described above is safe with low complication rates. In one series of 55 patients with 81 intra-abdominal fistulas, only one postoperative death occurred (from anastomotic breakdown), demonstrating that resection-based management is well-tolerated 4.

Special Considerations

Internal fistulas to other organs (enterovesical, gastrocolic, duodenocolic) that cause severe or persistent symptoms require surgical intervention 1. These are not managed medically, though anti-TNF therapies show some promise specifically for enterovesical fistulas based on limited data 6.